Corcept Therapeutics Incorporated (NASDAQ:CORT) Signals Mixed Momentum After Oncology Approval
![]() |
Relacorilant’s regulatory win in ovarian cancer shifts near-term narrative toward commercialization while technical momentum and stretched fundamentals create a tight risk/reward window for the immediate future. |








